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ABSTRACT
Background: Transfemoral access is the preferred approach for 
transcatheter aortic valve implantation. However, some situations, 
such as the presence of peripheral vascular disease, preclude 
the use of such access. In these cases, subclavian access is 
an alternative approach for this procedure. This study aimed 
at evaluating the Brazilian experience using the subclavian 
approach for transcatheter CoreValve® prosthesis implantation. 
Methods: Aortic valve area < 1 cm2, aortic valve ring ≥ 20 
mm and ≤ 27 mm (26 mm and 29 mm CoreValve®), ascending 
aorta ≤ 43 mm and subclavian artery with a diameter ≥ 6 mm, 
without significant obstructive lesions, marked tortuosity and 
excess calcification were requisites for the procedure. The 
access through the subclavian artery was obtained by surgi-
cal dissection and, under direct vision, a subclavian artery 
puncture was performed. Once artery access was obtained, the 
standard technique was used. Results: Between January 2008 
and April 2012, 8 patients with peripheral vascular disease 
underwent CoreValve® prosthesis implantation through the 
subclavian artery in 4 institutions. The procedure was suc-
cessful in all cases with reduction of the mean transvalvular 
pressure gradient from 46.4 ± 17.5 mmHg to 9.3 ± 3.6 mmHg 
(P = 0.0018) and improvement of symptoms. At 30 days and 
after 275 ± 231 days of follow-up, 87.5% and 62.5% of the 
patients, respectively, were free from major adverse events 
(death, myocardial infarction, stroke and urgent cardiac sur-
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RESUMO
Acesso pela Artéria Subclávia para Implante  
por Cateter da Bioprótese Valvar Aórtica  
CoreValve®: Dados do Registro Brasileiro
Introdução: A via de acesso transfemoral é preferencial para 
o implante por cateter de bioprótese valvar aórtica. Entretanto, 
algumas situações, como a presença de doença vascular peri-
férica, impossibilitam a utilização desse acesso. Nesses casos, 
o acesso por dissecção da artéria subclávia é uma alternativa 
para a realização do procedimento. Nosso objetivo foi avaliar 
a experiência brasileira com a utilização da artéria subclávia 
como via de acesso para o implante por cateter da bioprótese 
CoreValve®. Métodos: Foram requisitos para o procedimento 
área valvar aórtica < 1 cm², ânulo valvar aórtico > 20 mm e 
< 27 mm (CoreValve® de 26 mm e 29 mm), aorta ascendente 
< 43 mm e artéria subclávia com diâmetro > 6 mm, isenta 
de lesões obstrutivas significativas, tortuosidade acentuada e 
calcificação excessiva. O acesso pela artéria subclávia foi obtido 
por dissecção cirúrgica e, sob visão direta, punção da artéria 
subclávia. Obtido o acesso arterial, empregou-se a técnica 
padrão. Resultados: Entre janeiro de 2008 e abril de 2012, 8 
pacientes com doença vascular periférica foram submetidos a 
implante de prótese CoreValve® pela artéria subclávia em 4 
instituições. O procedimento foi realizado com sucesso em todos 
os casos, com redução do gradiente transvalvar aórtico médio 
de 46,4 + 17,5 mmHg para 9,3 + 3,6 mmHg (P = 0,0018) e 
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gery). Conclusions: In the Brazilian experience, the subclavian 
access was a safe and effective alternative for transcatheter 
CoreValve® implantation.
 
 
 
DESCRIPTORS: Aortic valve stenosis. Subclavian artery. Heart 
valve prosthesis.
melhora dos sintomas. Aos 30 dias e no seguimento de 275 
+ 231 dias, 87,5% e 62,5% dos pacientes, respectivamente, 
apresentavam-se livres de complicações maiores (óbito, infarto 
do miocárdio, acidente vascular cerebral e cirurgia cardíaca 
de urgência). Conclusões: Na experiência brasileira, o acesso 
pela artéria subclávia mostrou-se seguro e eficaz como via 
alternativa para o implante por cateter da bioprótese CoreValve®.
DESCRITORES: Estenose da valva aórtica. Artéria subclávia. 
Próteses valvulares cardíacas.
T ranscatheter aortic valve implantation is a safe and effective procedure for the treatment of patients with symptomatic aortic stenosis that is either 
inoperable or that carries a high surgical risk.1,2 For 
this procedure, the femoral approach is preferred, since 
it is less invasive. However, some situations, such as 
the presence of atheromatous disease, tortuosity, and 
calcification in the territories of the femoral and iliac 
arteries, prevent the procedure from being performed 
through the femoral artery. In these cases, alternative 
access routes can be used, such as the transapical and 
transaortic routes.1,3,4 However, complications arising 
from the thoracotomy and the incision in the left 
ventricular apex are not uncommon with these tech-
niques.5,6 Access through dissection of the subclavian 
artery has been described as a less invasive option 
and therefore more attractive for the implantation of 
the CoreValve® bioprosthesis (CoreValve® Revalving 
System, Medtronic, Inc. – Minneapolis, USA).7–11 In 
this study, the Brazilian experience with the use of 
the subclavian artery as an access route for CoreV-
alve® bioprosthesis implantation is reported, with data 
obtained from the Brazilian Registry of Transcatheter 
Aortic Valve Bioprostheses Implantation.12 
Methods
Patient selection
Patients in whom the subclavian artery was used 
as an access for CoreValve® bioprosthesis implantation 
were selected for this study from the Brazilian regis-
try. The subclavian artery was used only when there 
were contraindications to femoral access, and when-
ever possible, the left subclavian access was chosen. 
Patients considered to be suitable for the procedure 
were those with aortic valve area < 1 cm2, annular 
aortic valve ≥ 20 mm and ≤ 27 mm (CoreValve® of 
26 mm and 29 mm), ascending aorta ≤ 43 mm, and 
subclavian artery diameter ≥ 6 mm, free of significant 
obstructive lesions, severe tortuosity, and excessive 
parietal calcification. 
The EuroSCORE and STS scores were used to 
estimate the risk of surgical mortality in this series of 
patients.13,14
Procedure
Preparation for the procedure consisted of antibiotic 
and antiplatelet therapy with aspirin and/or clopidogrel. 
The valve implantations were performed under general 
anaesthesia. Alternative access through the subclavian artery 
was obtained by surgical dissection. For the dissection, 
an infraclavicular incision was used. Under direct vision, 
the subclavian artery was punctured for the positioning 
of the 18 F sheath or, when the artery was deep, a Da-
cron graft was anastomosed to the artery and used for 
insertion of the 18 F sheath (Figure 1). After obtaining 
arterial access, the standard technique (Figure 2) was 
used for the CoreValve® bioprosthesis implantation, which 
consists of three porcine pericardium leaflets, mounted 
and sutured into an auto-expansible nitinol stent 5 cm 
in length. At the end of the procedure, the 18 F sheath 
was removed, and the subclavian artery was sutured.
data collection and outcomes
Clinical data and information on complementary 
exams were collected during medical appointments or 
by telephone contact and entered into an electronic 
spreadsheet developed for the Brazilian Registry. All 
outcomes and complications followed the criteria es-
tablished by the Valve Academic Research Consortium 
Consensus on Definition Event Event (VARC).15
statistical analysis
Continuous variables are shown as the mean 
± standard deviation, and categorical variables are 
shown as frequencies (number and percentage). For 
the comparative analysis of categorical variables, the 
chi-squared or Fisher’s exact tests were used. For the 
sequential analysis of continuous variables in the same 
patient, a paired t-test was used. The significance level 
was set at 5% (P < 0.05).
Results
Between January of 2008 and April of 2012, 277 
patients with aortic valve stenosis and either contrain-
dications for or high-risk for conventional surgical 
treatment underwent transcatheter CoreValve® biopros-
thesis implantation in 12 centres, and were included 
in the Brazilian Registry. At four of these ins titutions, 
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the subclavian access route was used for the treat-
ment of eight (2.9%) patients: two (25%) through the 
right subclavian artery and six (75%) through the left 
subclavian artery.
The basal demographic and clinical characteristics of 
the eight patients receiving the CoreValve® bioprosthesis 
implant through the subclavian artery are described in 
Table 1. The high surgical risk in this group of patients 
was demonstrated by the EuroSCORE and STS risk scores, 
which were both above 30%. The contraindication for 
femoral access was the presence of peripheral vascular 
disease, and three (37.5%) of the patients also had an 
abdominal aortic aneurysm.
The mean hospital stay was 14 ± 12.9 days (one 
to 43 days). The mean follow-up of patients was 275 
± 231 days (one to 679 days). The one-month, one-
year, and two-year follow-up data were available for 
seven (87.5%) patients, five (62.5%) patients, and one 
(12.5%) patient, respectively. There was no loss of 
clinical follow-up in any case. 
Procedure
Data from the procedure are described in Table 2. 
Successful CoreValve® bioprosthesis implantation was 
achieved in 100% of the cases. In two (25%) cases 
it was necessary to perform post-dilation to properly 
expand the bioprosthesis and to reduce the intensity of 
the perivalvular insufficiency. Echocardiography detected 
the reduction of the mean and peak aortic transvalvular 
pressure gradients (Table 3). At the end of the proce-
dure, there was mild periprosthetic aortic regurgitation 
in six (75%) cases.
A B
C
A
C
B
D
Figure 1 – In A, subclavian artery dissection. In B, Dacron graft anastomosis. 
In C, 18 F sheath positioning in the subclavian artery through the graft.
Figure 2 – In A, aortography and placement of a guidewire inside the 
left ventricle. In B, introduction of the CoreValve® prosthesis for the left 
subclavian artery. In C, a prosthesis positioned in the aortic annulus. 
In D, aortography demonstrating a well-positioned and competent 
CoreValve® prosthesis.
TABLE 1 
Basal Demographic and Clinical Data
Characteristics n = 8
Age, years (SD) 84 (7.3)
Male gender, n (%) 5 (62.5)
Logistic EUROSCORE, % (SD) 32 (16.4)
STS score, % (SD) 30.9 (23.4)
Functional Class (NYHA), n (%)
I or II 0 (0)
III or IV 8 (100)
Diabetes, n (%) 3 (37.5)
Arterial hypertension, n (%) 5 (62.5)
Renal failure*, n (%) 6 (75)
Coronary artery disease, n (%) 5 (62.5)
Previous percutaneous coronary 
intervention 2 (25)
CABG 2 (25)
Cerebrovascular disease, n (%) 1 (12.5)
Peripheral vascular disease, n (%) 7 (87.5)
Chronic obstructive pulmonary 
disease, n (%) 2 (25)
Definitive pacemaker, n (%) 1 (12.5)
*Glomerular filtration rate < 60 mL/min.
SD = standard deviation; n = number of patients; NYHA = New 
York Heart Association; CABG = coronary artery bypass graft. 
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outcomes and complications
The transcatheter treatment of aortic valve stenosis 
was effective at alleviating the symptoms of heart failure. 
After 30 days and during follow-up, 85.7% of patients 
achieved functional class status I or II of the New York 
Heart Association (NYHA) criteria (P = 0.0007 vs. baseline).
Table 4 illustrates the complications that occurred 
within 30 days and during follow-up. During the proce-
dure, one case of subclavian artery dissection occurred 
and was corrected with stenting, and one patient had 
bleeding that required a transfusion. One death from 
cardiovascular causes occurred one day after the proce-
dure in a patient who developed refractory cardiogenic 
shock after valve implantation. Thus, mortality at 30 days 
was 12.5%. Two other deaths from non-cardiovascular 
causes occurred 43 and 679 days after the CoreValve® 
bioprosthesis implantation.
Two patients had renal failure after the procedure, 
one of which was associated with refractory cardiogenic 
shock and death, as previously described. None of the 
cases had a stroke, acute myocardial infarction (AMI), or 
the need for urgent heart surgery; thus, throughout the 
275 ± 231 days of follow-up, five (62.5%) patients were 
free of major complications. In this series, excluding the 
patient who died one day after the procedure and one 
patient who was already using a pacemaker, two (33.3%) 
underwent implantation of a permanent pacemaker for 
advanced atrioventricular conduction disturbances.
discussion
The current versions of both devices available for 
clinical use, CoreValve® and Edwards SAPIEN (Edwards 
Lifesciences – Irvine, USA), with 18 F delivery systems 
(6 mm), allow the procedure to be performed through 
the femoral artery, as long as the arterial lumen diam-
eter is at least 6 mm. However, in this population of 
patients of advanced age and with multiple comorbidi-
ties, it is not uncommon to find severe atheromatosis 
or excessive tortuosity, which prevent the procedure 
from being performed by this access route. In this case, 
access through the subclavian artery for CoreValve® 
bioprosthesis aortic implantation is a feasible, safe, 
and effective procedure, as demonstrated by several 
series and also by the present study with data from the 
Brazilian registry.9–11 In international records, subclavian 
access is employed in approximately 5% of cases, and 
the patients have, in general, a higher surgical risk than 
patients in whom femoral access was used.9–11,16–19 In 
the Brazilian Registry, only 2.9% of cases were treated 
using the subclavian artery, which is most likely due 
to the lower experience of centres with this alternative 
access route. As with the international series, patients 
from the Brazilian Registry treated through subclavian 
access had a very high surgical mortality risk, over 
30%, demonstrating that the presence of peripheral 
vascular disease is also a marker of higher clinical and 
anatomic complexity.20
TABLE 2 
Procedure Data
Characteristics n = 8
Proctor follow-up, n (%) 3 (37.5)
Transesophageal echocardiogram, n (%) 5 (62.5)
Anaesthesia, n (%)
General 8 (100)
Sedation 0 (0)
Access route, n (%)
Percutaneous 0 (0)
Surgical 8 (100)
Valvuloplasty, n (%) 5 (62.5)
Bioprosthesis, n (%)
CoreValve® 26 mm 3 (37.5)
CoreValve® 29 mm 5 (62.5)
Post-dilation,  n (%) 2 (25)
Device success, n (%) 8 (100)
n = number of patients.
TABLE 3 
Echocardiographic Data
Basal
(n = 8)
Post-implantation
(n = 7) P
Aortic valve area, cm3 (SD) 0.7 (0.2) NA
Peak gradient, mmHg (SD) 73.6 (27.8) 17.8 (7.5) < 0.001
Mean gradient, mmHg (SD) 46.4 (17.5) 9.3 (3.6) 0.0018
LVEF, % (SD) 58.7 (9.2) 63.4 (12.4) 0.175
SD = standard deviation; LVEF = left ventricular ejection fraction; n = number of patients; NA = not available. 
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As a positive point regarding access through the 
subclavian artery, it should be emphasized that it is 
easier to control the stent at the time of its release in 
the valvular annulus when compared with femoral ac-
cess, as the shorter distance and less tortuous path allow 
better transmission of force to the distal system portion, 
allowing for a more accurate positioning. Moreover, 
in general, the subclavian arteries are less affected by 
atheromatosis than the iliac and femoral arteries.
When selecting access through the subclavian ar-
tery, there is a preference for the left artery because, 
intuitively, there would be less risk of stroke than when 
using the right subclavian artery, considering that the 
presence and manipulation of the prosthesis delivery 
device in the brachiocephalic trunk could cause em-
bolization and limit flow into the right carotid. In this 
case, access through the right artery is feasible only 
when the diameter of the brachiocephalic trunk artery 
is > 7 mm and free of significant atheromatosis.
Another point in favor of using the left subclavian 
artery as the access route is the more favorable orientation 
of the bioprosthesis in the valve annulus at the implan-
tation, similar to the positioning obtained by a femoral 
approach. Therefore, the right subclavian artery should 
be considered as a good alternative only in cases where 
the presence of atheromatous disease or tortuosity prevent 
implantation through the left subclavian artery, or in cases 
where the diameter of the left subclavian is < 7 mm 
in the presence of a patent internal thoracic artery graft to 
a coronary artery of major anatomical importance, due to 
the incapacity of accommodating the prosthesis-releasing 
device (6 mm) and maintaining blood flow to the graft. In 
the present study, following this recommendation, the right 
subclavian artery access was used in only 25% of cases.
More recently, the use of the subclavian artery 
for CoreValve® bioprosthesis implantation by totally 
percutaneous access and hemostasis obtained after the 
procedure with ProstarTM haemostatic devices (Abbott 
Vascular – Abbott Park, USA) or ProGlideTM (Abbott Vas-
cular – Abbott Park, USA) has been reported.21 However, 
validation of this approach also depends on the confirma-
tion of its safety, since severe bleeding complications may 
result from the failure of the device to perform hemostasis.
conclusions
In the Brazilian experience, transcatheter CoreValve® 
bioprosthesis implantation through the subclavian artery 
route was safe and effective for use in selected patients 
in whom femoral access was not feasible. This alterna-
tive access route allows for a larger number of patients 
to benefit from aortic valve bioprosthesis transcatheter 
implantation.
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